Scott analyzes the implications of the FDA ending compounded GLP-1 weight loss drugs, which have provided a cheaper alternative to official channels for the past three years, and examines various responses from both compounding pharmacies and pharmaceutical companies. Longer summary

Scott discusses the upcoming end to compounded GLP-1 weight loss drugs in the US, as the FDA declares the shortage over. He explains how for the past three years, compounding pharmacies have provided these drugs at $200/month compared to the official $1000/month price, helping about 2 million Americans. The post explores various strategies companies are using to try to continue providing cheaper alternatives, and how pharmaceutical companies are responding with their own direct-to-consumer models. Scott concludes by noting how this experiment in semi-free-market medicine has shown that a less regulated supply chain can work effectively. Shorter summary

Scott Alexander examines the surprisingly broad effects of GLP-1 drugs like Ozempic, exploring their mechanisms and speculating on why they seem to impact so many different conditions. Longer summary

Scott Alexander explores the wide-ranging effects of GLP-1 receptor agonist medications like Ozempic, which are approved for diabetes and obesity but show promise for many other conditions. He delves into the mechanisms behind their effects on diabetes, weight loss, and addiction, speculating on why these drugs seem to have such broad impacts. The post discusses how GLP-1 drugs work in the brain to reduce hunger and dampen reward systems, potentially explaining their effects on addiction. Scott also touches on their anti-inflammatory properties and potential benefits for neurodegenerative diseases, while cautioning that some reported effects may not replicate. Shorter summary